12 Health Care Stocks Moving In Thursday’s After-Market Session
Gainers
ContraFect (NASDAQ:CFRX) stock increased by 4.9% to $2.76 during Thursday's after-market session. The company's market cap stands at $108.5 million.
18 Stocks Moving in Friday’s Pre-Market Session
Gainers
Medalist Diversified REIT, Inc. (NASDAQ: MDRR) rose 34.3% to $1.37 in pre-market trading after the company reported a stock repurchase program of 500,000 shares.
63 Biggest Movers From Yesterday
Gainers
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) shares surged 93.2% to close at $1.70 on Thursday. Kiora Pharmaceuticals recently appointed David Hollander, MD, MBA, to its Board of Directors.
44 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) jumped 52.3% to $1.3396. Kiora Pharmaceuticals recently appointed David Hollander, MD, MBA, to its Board of Directors.
20 Stocks Moving in Thursday’s Pre-Market Session
Gainers
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) rose 33.6% to $3.10 in pre-market trading. BiondVax reported successful closing of $9.8 million follow-on underwritten offering of ADSs including exercise of the over-allotment.
45 Biggest Movers From Yesterday
Gainers
Insignia Systems, Inc. (NASDAQ: ISIG) shares climbed 64.8% to close at $19.02 on Tuesday as traders circulated a social media post on a potential short squeeze.
25 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 64.6% to $18.99 as traders circulated a social media post on a potential short squeeze.
Mid-Morning Market Update: Markets Mostly Higher; Digital Turbine Reports Multi-Year Collaboration With Google
Following the market opening Tuesday, the Dow traded up 0.48% to 36,476.04 while the NASDAQ fell 0.13% to 15,850.57. The S&P also rose, gaining 0.10% to 4,795.90.
Benzinga Pro’s Top 5 Stocks To Watch For Tuesday, Dec. 28, 2021: KNSA, BVXV, FTK, APPS, MBOT
Today's 5 Stock Ideas:
Kiniksa Pharmaceuticals (KNSA) - Shares down ~14% premarket. The company announced the Phase 3 trial of mavrilimumab in COVID-19-related ARDS did not meet the primary efficacy endpoint.